The first two days of the New Year ushered in hundreds of price hikes across the drug industry, and the tally has just kept growing.
So far this month, 471 meds have bigger stickers now than they did a week ago, an update from GoodRx shows. On average, the increases came in at 5.1%. And as Reuters reports, Novartis, Merck & Co. and Allergan Friday joined the list of companies raising prices.
Novartis is marking up prices on about 7% of the products it sells in the U.S., a spokesperson told FiercePharma. Overall, the drugmaker expects U.S. net pricing—the amount it reaps after rebates and discounts—to decline by 2.5% during 2020.
Merck is raising prices on about 15 medicines, Reuters reports. The hikes are within the company’s pledge to limit price hikes to U.S. inflation, a spokeswoman said. The drugmaker is “committed to working with policymakers and stakeholders at both the federal and local levels on solutions that will address patient out-of-pocket costs,” she added.
For its part, Allergan is raising prices by 25 drugs by 5%—plus two others by 2% to 3%, a spokeswoman said. The drugmaker still expects net pricing to be flat or decline this year on higher rebates and discounts.
The Friday hikes by Allergan, Merck and Novartis followed similar moves by Pfizer, Bristol-Myers Squibb, AbbVie, Gilead Sciences and others.
The most commonly prescribed drugs carrying higher prices include Pfizer and Bristol-Myers Squibb’s Eliquis, Eli Lilly and Boehringer Ingelheim’s Jardiance, BI’s Tradjenta, Gilead’s Truvada and Pfizer’s Chantix, according to GoodRx.
All but a few of the price hikes are under 10%, a level famously set years back by Allergan CEO Brent Saunders in his pledge about pharma’s “social contract.” Some of them pushed right up to that threshold, though, with increases of 9.9%.
All of the increases apply to list prices, which are negotiated down by middlemen and payers. Patients typically don’t pay list prices.
Still, the steady stream of price hikes has angered lawmakers, patients and public health advocates. Patients 4 Affordable Drugs Executive Director Ben Wakana said in a news statement that the pharma industry “can’t break its addiction to price increases.”
The hikes show the industry can’t be trusted to police itself, Wakana said, adding that it’s time for Congress to pass legislation to stop the industry’s “price gouging.”
By Eric Sagonowsky
Source: Fierce Pharma
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
